Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | USP2 | O75604 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | XBP1 | P17861 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.38 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3862847 | 0.86 | L3MBTL1 (0.53) | L3MBTL1HSD17B10ALDH1A1KDM4ETSHR | |
| SCHEMBL1930206 | 0.86 | L3MBTL1 (0.48) | L3MBTL1HSD17B10ALDH1A1KDM4ETSHR | |
| SCHEMBL1929051 | 0.84 | L3MBTL1 (0.51) | L3MBTL1HSD17B10ALDH1A1KDM4ETSHR | |
| SCHEMBL1930432 | 0.82 | L3MBTL1 (0.58) | L3MBTL1HSD17B10ALDH1A1KDM4ETSHR | |
| SCHEMBL1930420 | 0.82 | L3MBTL1 (0.49) | L3MBTL1HSD17B10ALDH1A1KDM4ETSHR | |
| SCHEMBL1930375 | 0.82 | ALDH1A1 (0.49) | L3MBTL1HSD17B10ALDH1A1KDM4ETSHR | |
| SCHEMBL1928761 | 0.82 | L3MBTL1 (0.57) | L3MBTL1HSD17B10ALDH1A1KDM4ETSHR | |
| SCHEMBL1930363 | 0.82 | NPC1 (0.50) | L3MBTL1HSD17B10ALDH1A1KDM4ETSHR | |
| SCHEMBL1930307 | 0.81 | L3MBTL1 (0.56) | L3MBTL1HSD17B10ALDH1A1KDM4ETSHR | |
| SCHEMBL1930148 | 0.80 | L3MBTL1 (0.55) | L3MBTL1HSD17B10ALDH1A1KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1968972-B1 | ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2012-11-28 | — | — | EP | claimed |
| US-7541372-B2 | Aryl-isoxazolo-4-yl-oxadiazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-06-02 | — | — | US | claimed |
| US-20070161686-A1 | Aryl-isoxazolo-4-yl-oxadiazole derivatives | HOFFMANN-LA ROCHE INC. | 2007-07-12 | — | — | US | claimed |
| EP-1968972-B1 | ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2012-11-28 | — | — | EP | disclosed |
| US-7956074-B2 | Aryl-isoxazolo-4-yl-oxadiazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-06-07 | — | — | US | disclosed |
| US-20090197875-A1 | ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES | BUETTELMANN BERND | 2009-08-06 | — | — | US | disclosed |
| US-7541372-B2 | Aryl-isoxazolo-4-yl-oxadiazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-06-02 | — | — | US | disclosed |
| EP-1968972-A1 | ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| US-20070161686-A1 | Aryl-isoxazolo-4-yl-oxadiazole derivatives | HOFFMANN-LA ROCHE INC. | 2007-07-12 | — | — | US | disclosed |
| WO-2007071598-A1 | ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197875-A1 | ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES | GABRA5, GABRA4, GABRA3 | L3MBTL1 3503/4885HSD17B10 810/4885ALDH1A1 310/4885 |
| US-20070161686-A1 | Aryl-isoxazolo-4-yl-oxadiazole derivatives | GABRA5, GABRA4, GABRA3 | L3MBTL1 3503/4885HSD17B10 810/4885ALDH1A1 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.